ArticleEJHaem2026
Polatuzumab Vedotin Enhances Intratumoral T-Cell Infiltration and Demonstrates Combinatorial Efficacy With Anti-CD20/CD3 Bispecific Antibody in a Syngeneic B-Cell Malignancy Mouse Model.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Polatuzumab vedotin (Pola) is an anti-CD79b antibody-drug conjugate. Clinical evidence supports the combination efficacy of Pola with mosunetuzumab or glofitamab, both anti-CD20/CD3 bispecific antibodies (anti-CD20/CD3 BsAbs). However, the influence of Pola on the tumor microenvironment and its impact on the efficacy of anti-CD20/CD3 BsAb remains unclear. Results: In a syngeneic mouse model, Pola significantly increased tumor-infiltrating T cells and innate immune cells. Moreover, Pola also upregulated the levels of cytokine and chemokine involved in T-cell infiltration. The Pola + anti-CD20/CD3 BsAb combination showed superior anti-tumor efficacy versus each monotherapy. Conclusion: These findings suggest Pola enhances immune cell infiltration into tumors and could enhance the efficacy of anti-CD20/CD3 BsAb. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.